PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY

Xuezhen Zhu; Yu Wai Chen; William Tak Hang Chan; Ming Cheung Chow

PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY

Xuezhen Zhu (Inventor), Yu Wai Chen (Inventor), William Tak Hang Chan (Inventor), Ming Cheung Chow (Inventor)

Department of Applied Biology and Chemical Technology

Research output: Patents, agreements, assignments and companies › Patents granted

Abstract

Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.

Original language	English
Patent number	US 11,117,932
Priority date	20/07/18
Filing date	19/07/19
Publication status	Published - 14 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{bd75f9bf0428460cb8bbb81e51598907,

title = "PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY",

abstract = "Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.",

author = "Xuezhen Zhu and Chen, {Yu Wai} and Chan, {William Tak Hang} and Chow, {Ming Cheung}",

year = "2021",

month = sep,

day = "14",

language = "English",

type = "Patent",

note = "US 11,117,932",

}

TY - PAT

T1 - PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY

AU - Zhu, Xuezhen

AU - Chen, Yu Wai

AU - Chan, William Tak Hang

AU - Chow, Ming Cheung

PY - 2021/9/14

Y1 - 2021/9/14

N2 - Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.

AB - Aberrant cross talk between Notch ligand (e.g. Jag1) and Notch receptor (e.g. Notch1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregulated Jag1 e.g. colorectal cancer (CRC). Pan-notch inhibitors like gamma secretase inhibitors (GSIs) have been developed to inhibit Notch and its downstream events. However, severe gastrointestinal toxicity profiles impede the clinical development of GSIs. The present invention develops novel oligopeptides that specifically inhibit Jag1-Notch1 pathway without interfering DLL1-Notch1 or DLL4-Notch1, which demonstrates a clear advantage over pan-notch inhibitors.

M3 - Patents granted

M1 - US 11,117,932

Y2 - 2019/07/19

ER -

PEPTIDES FOR SPECIFIC INHIBITION OF JAG1-NOTCH1 PATHWAY

Abstract

UN SDGs

Fingerprint

Cite this